Xenon Pharmaceuticals Inc. has announced the establishment of a new collaboration with Genentech, a member of the Roche Group, for pain genetics, with the goal of discovering and validating new therapeutic targets and mechanisms for treating pain.
The collaboration leverages Xenon’s Extreme Genetics discovery platform to focus on rare phenotypes where individuals have an inability to perceive pain or where individuals have non-precipitated spontaneous severe pain.
This new collaboration agreement builds on the strategic alliance established between Xenon and Genentech in 2012 for the discovery and development of compounds and companion diagnostics for the potential treatment of pain.
“With this new collaboration, we have the opportunity to apply our expertise in pain genetics and insights into the biology of pain more broadly, and build on our highly productive strategic alliance with Genentech,” said Dr. Simon Pimstone, President and Chief Executive Officer of Xenon.
Dr. Pimstone continued, “We believe the pain market is currently underserved and represents a significant commercial opportunity for our company. We look forward to working further with Genentech to seek to discover additional highly validated targets that could yield novel non-opioid based mechanisms to treat pain.”
Pursuant to the terms of the new agreement, both Xenon and Genentech will own the intellectual property arising out of the collaboration.
Xenon has also granted Genentech a time-limited, exclusive right of negotiation on a target-by-target basis to form joint drug discovery collaborations. Financial terms of the agreement were not disclosed.